Fluvastatin and the Breast Cancer Risk:A Meta-analysis of Observational Studies

被引：0

作者：

DongMei Liu ^{[1
]}

Jian Zhang ^{[2
]}

Wei Zhang ^{[3
]}

James Lu ^{[4
]}

JianLun Han ^{[2
]}

GuangJun Hao ^{[1
]}

ShengMing Ye ^{[2
]}

机构：

[1] Oncology Department of Yulin First Hospital,Second Affiliated Hospital of Yanan University

[2] Cardiology Department of Yulin First Hospital,Second Affiliated Hospital of Yanan University

[3] Pharmacy Department of Yulin First Hospital,Second Affiliated Hospital of Yanan University

[4] Foreign languages institute of Yulin university

来源：

World Journal of Traditional Chinese Medicine | 2016年 / 2卷 / 03期

关键词：

Fluvastatin; Breast cancer; Meta-analysis;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 ;

摘要：

Multiple studies have investigated the associations between fluvatatin and the risk of breast cancer(BC),but their results were conflicting.A meta-analysis of observational studies published regarding this subject was conducted in the present study.It aims to estimate the associations between fluvastatin use and the risk of BC.Pubmed and chinese national knowledge infrastructure(CNKI) database was searched up to January,2015 to identify eligible observational studies,and the Newcastle-Ottawa Scale(NOS) was used to assess quality of the studies.Pooled relative risk(RR) estimates and 95% confidence intervals(CIs) were calculated(fixed effect model:Mantel-Haenszel).Heterogeneities were evaluated before the calculation.A sensitivity analysis was also conducted.In total,four studies contributed to the analysis.Overall,fluvastatin use negatively correlated with BC risk(RR = 0.74,95 % CI = 0.58,0.95).In conclusion,fluvastatin use may reduce the risk of BC,but more research is needed to confirm this finding.

引用

页码：43 / 47

页数：5

共 12 条

[1]

Novel prospects of statins as therapeutic agents in cancer[J] . Simona Pisanti,Paola Picardi,Elena Ciaglia,Alba D’Alessandro,Maurizio Bifulco. Pharmacological Research . 2014

[2]

Statin‐induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms[J] . Anantha Koteswararao Kanugula,Paradesi Naidu Gollavilli,Sathish Babu Vasamsetti,Santosh Karnewar,Raja Gopoju,Ramesh Ummanni,Srigiridhar Kotamraju. FEBS J . 2014 (16)

[3] Fluvastatin inhibits growth and alters the malignant phenotype of the C6 glioma cell line [J].

Slawinska-Brych, Adrianna ;

Zdzisinska, Barbara ;

Kandefer-Szerszen, Martyna .

PHARMACOLOGICAL REPORTS, 2014, 66 (01) :121-129

[4] Pharmacometabolomics of Statin Response [J].

Krauss, R. M. ;

Zhu, H. ;

Kaddurah-Daouk, R. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (05) :562-565

[5]

Statin use and risk of breast cancer: a meta-analysis of observational studies[J] . Krishna Undela,Vallakatla Srikanth,Dipika Bansal. Breast Cancer Research and Treatment . 2012 (1)

[6]

Statin use and cancer risk: a comprehensive review[J] . Denise M Boudreau,Onchee Yu,Jeanene Johnson. Expert Opinion on Drug Safety . 2010 (4)

[7] Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer [J].

Garwood, Elisabeth R. ;

Kumar, Anjali S. ;

Baehner, Frederick L. ;

Moore, Dan H. ;

Au, Alfred ;

Hylton, Nola ;

Flowers, Chris I. ;

Garber, Judy ;

Lesnikoski, Beth-Ann ;

Hwang, E. Shelley ;

Olopade, Olofunmilao ;

Port, Elisa Rush ;

Campbell, Michael ;

Esserman, Laura J. .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) :137-144

[8]

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins[J] . The Lancet . 2005 (9493)

[9]

Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study[J] . Christophe Denoyelle,Marc Vasse,Marie K&ouml,rner,Zohair Mishal,Florence Gann&eacute,Jean-Pierre Vannier,Jeannette Soria. Carcinogenesis . 2001

[10]

The Newcastle-Ottawa Scale (NOS)for assessing the quality of nonrandomized studies in meta-analyses .2 Wel s GA,Shea B,O’’Connell D,Peterson J,Welch V,et al. http://www.ohri.ca/programs/clinicalepidemiology/oxford.asp .

← 1 2 →